Pasithea Therapeutics Corp. (KTTA) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated May 6, 2025, details a material definitive agreement entered into by Pasithea Therapeutics Corp. The company, an emerging growth company incorporated in Delaware, completed a best efforts public offering of securities on May 7, 2025. The filing discloses the terms of the securities purchase agreements and the closing of the capital raise.
Key Financial Metrics and Transaction Details
The offering consisted of common stock, pre-funded warrants, and two series of common warrants. Key financial figures from the transaction include:
- Aggregate Gross Proceeds: Approximately $6.3 million (including proceeds from the offering and the simultaneous exercise of Series D warrants).
- Net Proceeds: Approximately $4.3 million (after deducting placement agent fees and estimated offering expenses, excluding warrant exercise proceeds).
- Securities Issued:
- 3,094,284 shares of Common Stock.
- 477,144 Pre-Funded Warrants (exercised immediately for 477,144 shares).
- 3,571,428 Series C Common Warrants (Exercise Price: $1.40; Expiration: 5 years).
- 3,571,428 Series D Common Warrants (Exercise Price: $1.40; Expiration: 18 months).
- Offering Price: $1.40 per share (Common Stock) and $1.399 per Pre-Funded Warrant.
- Additional Proceeds: Approximately $1.3 million from the immediate exercise of 914,286 Series D warrants by certain investors.
Material Changes and Use of Proceeds
The primary material change is the significant increase in cash liquidity and the dilution of existing shareholders due to the issuance of new equity and warrants. The company intends to use the net proceeds for general corporate purposes, specifically:
- Ongoing research and pre-clinical studies.
- Clinical trials and development of new biological and pharmaceutical technologies.
- Licensing activities and potential acquisitions of synergistic companies.
- Working capital.
The filing does not provide comparative financial metrics (revenue, profit, or margins) as this is a transactional report rather than a periodic financial statement.
Guidance, Risks, and Covenants
Management Commentary and Covenants:
- Lock-up Period: The Company agreed not to issue or announce the issuance of any shares of Common Stock or convertible securities for 90 days following the closing date, subject to exceptions.
- Variable Rate Transaction Restriction: The Company is restricted from entering into Variable Rate Transactions for one year from the closing date.
- Beneficial Ownership Limitations: Holders cannot exercise warrants if it would result in beneficial ownership exceeding 4.99% (or 9.99% at election) of outstanding shares, unless a 61-day notice period is observed to increase the limit.
Placement Agent Fees:
- H.C. Wainwright & Co., LLC served as the exclusive placement agent.
- Fees included a 7.0% cash fee and a 1.0% management fee on aggregate gross proceeds.
- The Company issued 250,000 Placement Agent Warrants (Exercise Price: $1.75; Term: 5 years).
- Reimbursements included $25,000 for expenses, $100,000 for legal fees, and $15,950 for clearing expenses.
Investor Verification Checklist
- Verify the exact number of shares outstanding post-offering to calculate the dilution impact of the 3,571,428 Series C and Series D warrants.
- Confirm the cash balance on the company's balance sheet following the closing of the $4.3 million net proceeds.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific exceptions to the 90-day lock-up and one-year variable rate transaction restrictions.
- Monitor the exercise of the 3,571,428 Series D warrants within the 18-month window, which could result in further dilution.
- Check subsequent filings for updates on the specific allocation of funds to clinical trials versus general working capital.